FindTrial
Sign In

IGlarLixi

DRUG6 trials

Sponsors

Population Health Research Institute, University Hospital Tuebingen, University of Campania Luigi Vanvitelli, Chungbuk National University Hospital, Institute for Clinical and Experimental Medicine

Conditions

Diabetes Mellitus Type 2Diabetes Mellitus, Type 2Glucose, High BloodMetabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesType 2 Diabetes MellitusType 2 Diabetes Treated With Insulin

Phase 3

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
CompletedNCT03130426
Population Health Research InstituteType 2 Diabetes Mellitus
Start: 2017-06-27End: 2020-09-30Updated: 2020-11-13

Phase 4

Effects of Insulin Glargine and Lixisenatide on the Brain
TerminatedNCT03881995
University Hospital TuebingenDiabetes Mellitus, Type 2
Start: 2019-03-18End: 2020-06-29Updated: 2020-07-10
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
CompletedNCT04196231
University of Campania Luigi VanvitelliType 2 Diabetes
Start: 2019-11-27End: 2020-10-20Updated: 2020-10-22
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
NCT04893148
Chungbuk National University HospitalGlucose, High Blood, Type 2 Diabetes Mellitus
Start: 2020-05-26End: 2022-12-30Target: 40Updated: 2022-07-20
INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi
NCT04945070
Institute for Clinical and Experimental MedicineType 2 Diabetes Treated With Insulin
Start: 2021-07-31End: 2023-06-30Target: 96Updated: 2021-07-22
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease
Enrolling by invitationNCT07274644
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDiabetes Mellitus Type 2, Metabolic Dysfunction-Associated Steatotic Liver Disease
Start: 2025-03-29End: 2026-06-30Target: 36Updated: 2025-12-10

Related Papers

The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol
Diabetes Therapy2024-04-245 citations
BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes
Endocrine2023-10-038 citations